News
Speaking on third quarter earnings calls this week, Novo and Pfizer’s CEOs see little change to their Most Favored Nation drug pricing deals, which were signed with the Trump administration last year.
FEATURED STORIES
In its latest five-year plan, China has set its sights on developing five drugs that could each rake in more than $1 billion globally by 2030. Experts say it’s well on its way, with two medications having already met that bar.
By allowing compounding pharmacies to produce certain unapproved peptides, the Department of Health and Human Services could, in the short term, put patients in harm’s way. Longer term, the policy shift threatens the industry that brings new medicines to market.
A fresh FDA review for Biohaven’s embattled ataxia drug lifted the biotech’s shares, while a late-stage lung cancer miss battered ArriVent, which failed to rebound even after encouraging early ADC data.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Watching the baseball playoffs this week, I was struck by the parallels between the Los Angeles Dodgers and Eli Lilly. Both franchises spend a lot of money and always appear to come out on top.
THE LATEST
Pfizer is calling upon lessons learned from one of the first drugs ever made available on the internet—Viagra—as it commercializes a new obesity drug in China.
Compass Pathways revealed that an FDA filing for COMP360 will be complete “in the next two weeks,” with an expected drug launch in the first half of next year. The update follows a reported regulatory submission for Usona Institute’s own psilocybin candidate for depression on Monday.
Neurocrine Biosciences will conduct a new study for the rare disease drug Vykat to explore dosing and safety in patients with Prader-Willi syndrome who have complex health issues.
Novartis is discontinuing a neurodegeneration alliance with BioArctic in which the companies aimed to develop a drug candidate that could cross the blood-brain barrier.
Sales of assets from Seagen and Biohaven grew in the third quarter, but it wasn’t enough for Pfizer to overcome declines across the Prevnar and COVID franchises.
Debtor-in-process financing up to $55 million could keep the lights on at Karyopharm Therapeutics for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with Ayrmid will go through.
The cessation of manufacturing activities follows a Sun Pharma recall and reports that regulators found fault with the company’s quality system.
In a mid-stage trial, the lower dose of Tiziana’s intranasal monoclonal antibody reduced microglial activation in a specific type of multiple sclerosis. But the path forward remains unclear after the higher dose failed to deliver the same benefit.
Sail Biomedicine’s $925 million deal with Johnson & Johnson helped boost the cell and gene therapy sector over biologics in terms of venture capital fundraising in the third quarter.
After a year of controversial regulatory reversals, the FDA has accepted uniQure’s application for ifezuntirgene inilparvovec for priority review, with a May 1 action date. If approved, the therapy—also called AMT-130—would be the first disease-modifying treatment for Huntington’s disease.